Literature DB >> 28436977

Provision of long-term monitoring and late effects services following adult allogeneic haematopoietic stem cell transplant: a survey of UK NHS-based programmes.

A Hamblin1, D M Greenfield2,3, M Gilleece4, N Salooja5, M Kenyon6, E Morris7, N Glover8, P Miller9, H Braund9, A Peniket1, B E Shaw10, J A Snowden3,11,12.   

Abstract

Despite international guidelines, optimal delivery models of late effects (LE) services for HSCT patients are unclear from the clinical, organizational and economic viewpoints. To scope current LE service delivery models within the UK NHS (National Health Service), in 2014, we surveyed the 27 adult allogeneic HSCT centres using a 30-question online tool, achieving a 100% response rate. Most LE services were led and delivered by senior physicians (>80% centres). Follow-up was usually provided in a dedicated allograft or LE clinic for the first year (>90% centres), but thereafter attrition meant that only ~50% of patients were followed after 5 years. Most centres (69%) had a standard operating procedure for long-term monitoring but access to a LE Multi-Disciplinary Team was rare (19% centres). Access to medical specialities necessary for LE management was good, but specialist interest in long-term HSCT complications was uncommon. Some screening (endocrinopathy, cardiovascular) was near universal, but other areas were more limited (mammography, cervical smears). Funding of extra staff and investigations were the most commonly perceived barriers to implementation of LE services. This survey shows variation in the long-term follow-up of allogeneic HSCT survivors within the UK NHS and further work is warranted to optimize effective, sustainable and affordable models of LE service delivery among this group.

Entities:  

Mesh:

Year:  2017        PMID: 28436977     DOI: 10.1038/bmt.2017.67

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  28 in total

1.  Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT).

Authors:  J D Rizzo; J R Wingard; A Tichelli; S J Lee; M T Van Lint; L J Burns; S M Davies; J L M Ferrara; G Socié
Journal:  Bone Marrow Transplant       Date:  2006-02       Impact factor: 5.483

2.  Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective.

Authors: 
Journal:  Bone Marrow Transplant       Date:  2009-10       Impact factor: 5.483

3.  Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface.

Authors:  M Tomblyn; T Chiller; H Einsele; R Gress; K Sepkowitz; J Storek; J R Wingard; J-A H Young; M J Boeckh
Journal:  Bone Marrow Transplant       Date:  2009-10       Impact factor: 5.483

Review 4.  Secondary cancers following allogeneic haematopoietic cell transplantation in adults.

Authors:  Navneet S Majhail
Journal:  Br J Haematol       Date:  2011-05-26       Impact factor: 6.998

5.  Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.

Authors:  Sherif S Farag; Kati Maharry; Mei-Jie Zhang; Waleska S Pérez; Stephen L George; Krzysztof Mrózek; John DiPersio; Donald W Bunjes; Guido Marcucci; Maria R Baer; Mitchell Cairo; Edward Copelan; Corey S Cutler; Luis Isola; Hillard M Lazarus; Mark R Litzow; David I Marks; Olle Ringdén; David A Rizzieri; Robert Soiffer; Richard A Larson; Martin S Tallman; Clara D Bloomfield; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2011-06-21       Impact factor: 5.742

6.  Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.

Authors:  John R Wingard; Navneet S Majhail; Ruta Brazauskas; Zhiwei Wang; Kathleen A Sobocinski; David Jacobsohn; Mohamed L Sorror; Mary M Horowitz; Brian Bolwell; J Douglas Rizzo; Gérard Socié
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

Review 7.  First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

Authors:  Paul J Martin; J Douglas Rizzo; John R Wingard; Karen Ballen; Peter T Curtin; Corey Cutler; Mark R Litzow; Yago Nieto; Bipin N Savani; Jeffrey R Schriber; Paul J Shaughnessy; Donna A Wall; Paul A Carpenter
Journal:  Biol Blood Marrow Transplant       Date:  2012-04-14       Impact factor: 5.742

8.  Late effects and healthcare needs of survivors of allogeneic stem cell transplantation: a qualitative study.

Authors:  Jessica P Hwang; Aimee K Roundtree; Sergio A Giralt; Maria Suarez-Almazor
Journal:  BMJ Support Palliat Care       Date:  2012-08-03       Impact factor: 3.568

Review 9.  Delivering care to long-term adult survivors of hematopoietic cell transplantation.

Authors:  Karen L Syrjala; Paul J Martin; Stephanie J Lee
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

Review 10.  Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist.

Authors:  Natasha Kekre; Joseph H Antin
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

View more
  3 in total

1.  The bone marrow transplant clinical nurse specialist in hemato-oncology: an interview with Anthony Nolan Nurse Specialist Susan Paskar.

Authors:  Susan Paskar
Journal:  Int J Hematol Oncol       Date:  2017-06-30

Review 2.  Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies.

Authors:  Courtney D Fitzhugh; Emmanuel J Volanakis; Ombeni Idassi; Josh A Duberman; Michael R DeBaun; Debra L Friedman
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

3.  Longitudinal proteomics study of serum changes after allogeneic HSCT reveals potential markers of metabolic complications related to aGvHD.

Authors:  Sing Ying Wong; Seiko Kato; Frans Rodenburg; Arinobu Tojo; Nobuhiro Hayashi
Journal:  Sci Rep       Date:  2022-08-17       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.